Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

Description

This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.

Conditions

Alzheimer Disease, Dementia, Major Neurocognitive Disorder With Aggressive Behavior

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Norfolk

Eastern Virginia Medical School, Norfolk, Virginia, United States, 23510

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Males/females over 50 years old.
  • * Have a diagnosis of dementia due to AD or mixed AD with another type of dementia.
  • * A Mini-Mental State Exam score (MMSE) between 4 and 28 inclusive.
  • * Presence of agitation with a Neuropsychiatric Inventory (NPI)-agitation/aggression subscore \> 3.
  • * Participants and their informal caregivers must be fluent in English (includes reading, writing, and speech) and able to give informed consent.
  • * For patients treated with cognitive-enhancing medications (cholinesterase inhibitors (ChEI) and/or memantine), the dosage must be stable for at least 1 month (30 days). If the ChEI and/or memantine has been discontinued, patients may enroll after 15 days.
  • * Eligible caregivers must either live with the participant or have a minimum of 4 hours of daily contact with them.
  • * Diagnosis of non-AD or non-mixed dementias.
  • * Very mild dementia or advanced dementia (MMSE: greater than 28 or less than 4).
  • * NPI-agitation-aggression score \< 3.
  • * Having a serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease which might confound assessment of safety outcomes as determined by the study physician.
  • * Presence or history of other serious psychiatric disorders or neurological conditions (e.g. psychotic disorders, bipolar disorder or schizophrenia).
  • * Current abuse of/dependence on marijuana, current drug abuse, current alcohol abuse.
  • * Having seizure disorders.
  • * Pregnant or breastfeeding
  • * Indication of baseline delirium as determined by the Confusion Assessment Method (CAM).
  • * Current use of lithium.
  • * Inability to swallow CBD oil softgels.
  • * Changes in dosage of anti-depressives within 4 weeks before randomization and during the study.
  • * Changes in dosage of antipsychotics or benzodiazepines within 1 week prior to randomization and during the study.
  • * Contraindications to CBD oil (history of hypersensitivity to any cannabinoid).
  • * Frequent falling due to orthostatic hypotension.
  • * Use of tricyclic antidepressants (TCA), fluoxetine, and/or carbamazepine. -Patients who reside in nursing homes.

Ages Eligible for Study

50 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eastern Virginia Medical School,

Hamid Okhravi, MD, PRINCIPAL_INVESTIGATOR, Eastern Virginia Medical School

Study Record Dates

2024-03